As attached.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natural Biocon reported zero revenue from operations in Q2 FY26 (₹0 lakhs), compared to ₹473.69 lakhs in Q2 FY25 and ₹166.57 lakhs in the preceding Q1 FY26. For H1 FY26, total revenue stood at ₹166.57 lakhs, a sharp drop from ₹572.34 lakhs in H1 FY25 (around 71% decline). The company slipped into a loss of ₹4.37 lakhs in Q2 FY26 versus a profit of ₹20.24 lakhs a year ago, though H1 FY26 remained marginally profitable at ₹9.49 lakhs. Basic EPS for the quarter was ₹(0.02). Operating cash flow stayed positive at ₹15.76 lakhs for H1 FY26, and the balance sheet remains debt-light with total equity of ~₹3,196 lakhs and negligible borrowings.
Zero top-line in Q2 FY26 is a serious red flag for investors — it suggests a near-complete halt in business activity during the quarter. The sharp revenue contraction and swing to loss could weigh negatively on sentiment and the stock price until clarity on operations emerges.